

RWANDA

Support for Inactivated Polio Virus Vaccine

This Decision Letter sets out the Programme Terms of a Programme

1. Country:	Rwanda						
2. Vaccine grant number:	19-RWA-25c-A, 20-RWA-25c-A						
3. Date of Decision Letter:	30 September 2019						
4. Date of the Partnership Framework Agreement:	7 June 2013						
5. Programme title:	New Vaccine Support (NVS), Inactivated Polio Virus, Routine (Fragility, emergencies and refugees policy)						
6. Vaccine type:	Inactivated Polio Virus						
7. Requested product presentation and formulation of vaccine:	Inactivated Polio Vaccine, 10 doses per vial, LIQUID						
8. Programme Duration:¹	2019-2020						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2019	2020	2021	2022	2023	2024	Total²
Programme Budget (US\$)	30,000	6,000	-	-	-	-	36,000
10. Vaccine introduction grant	Not applicable						
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						
Type of supplies to be purchased with Gavi funds	2019	2020					2021
Number of vaccine doses	13,100	2,700					-
Annual Amounts (US\$)	30,000	6,000					-
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.						

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

14. Self-procurement:	Not applicable										
15. Co-financing obligations:	<p>Not applicable</p> <p>Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.</p>										
16. Operational support for campaigns:	Not applicable										
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</td> <td></td> </tr> <tr> <td> <ul style="list-style-type: none"> Vaccine stock levels including buffer stock </td> <td>31 March 2020</td> </tr> <tr> <td> <ul style="list-style-type: none"> Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received </td> <td>15 May 2020</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>		Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year:		<ul style="list-style-type: none"> Vaccine stock levels including buffer stock 	31 March 2020	<ul style="list-style-type: none"> Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received 	15 May 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates										
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:											
<ul style="list-style-type: none"> Vaccine stock levels including buffer stock 	31 March 2020										
<ul style="list-style-type: none"> Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received 	15 May 2020										
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat										
18. Financial clarifications:	Not applicable										
19. Other conditions:	<p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p>										

Signed by

On behalf of Gavi



Thabani Maphosa

Managing Director, Country Programmes

30 September 2019

